| acute myocardial infarction | All results are NS for efficacy inferior to primary intervention in terms of Initial TIMI 3 flow in INTAMI (Zeymer), 2005 | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| INTAMI (Zeymer), 2005 | vs primary intervention | | Initial TIMI 3 flow 3.33 [1.34; 8.28] | Short-term death 0.92 [0.14; 6.31] Short-term major bleeding 0.92 [0.14; 6.31] Short-term non-fatal reinfarction ∞ [NaN; ∞] Short-term urgent target vessel revascularisation 1.85 [0.17; 19.76] Final TIMI 3 flow 1.04 [0.88; 1.23] |
| Trial | Treatments | Patients | Method |
|---|
| INTAMI (Zeymer), 2005 | facilated PCI with Eptifibatide; 180 µg/kg intravenous double bolus, 2·0 µg/kg per min infusion (n=53) vs. primary intervention (n=49) | symptom duration <12h | Sample size: 53/49 Primary endpoint: FU duration: 30-day |
|
| percutaneous coronary intervention | All results are NS for efficacy | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| vs placebo | | | | | vs placebo | | | | | vs placebo | | | | | vs placebo | | | |
| Trial | Treatments | Patients | Method |
|---|
| IMPACT (4h), 1995 | loading dose 90µg/kg infusion 1.0µg/kg/min for 4h (n=-9) vs. (n=-9) | Elective PCI | Sample size: -9/-9 Primary endpoint: FU duration: | | IMPACT-II (0.5µg), 1997 | loading dose 135µg/kg infusion 0.5µg/kg/min for 20-24h (n=-9) vs. (n=-9) | Any PCI | Sample size: -9/-9 Primary endpoint: FU duration: | | ESPRIT, 2000 | loading dose 180µg/kg x2 infusion 2µg/min for 18-24h (n=-9) vs. (n=-9) | Nonurgent PCI | Sample size: -9/-9 Primary endpoint: FU duration: | | Harrington, 1995 | loading dose µg/kg infusion µg/min for h (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
|
